BioSpace News Archive

The compact and portable nasal spray means it can be used directly before an anxiety-provoking trigger or at the beginning of an episode.

Seres Therapeutics, Inc. announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle.

Hanmi Fine Chemical a subsidiary of Hanmi Pharmaceutical Group specializing in APIs development and manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to ‘high-tech CDMO’ services.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, announced new data from its Revita-1 and Revita-2 studies.

Antengene Corporation Limited announces that the first patient has been dosed in the single-arm Phase I/II SWATCH Study, designed to evaluate the safety, tolerability and preliminary efficacy of XPOVIO® in combination with the R2 regimen of lenalidomide plus rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma and relapsed/refractory indolent non-Hodgkin lymphoma.